Transave, Inc. Receives Orphan Drug Designation From The FDA For SLIT(TM) Amikacin For Treatment Of Pulmonary Pseudomonas Aeruginosa Infections In Cystic Fibrosis Patients

MONMOUTH JUNCTION, New Jersey, March 23, 2006 -- Transave, Inc., a biopharmaceutical company focused on the development of inhaled, liposomally formulated drugs for treating life threatening lung diseases, today announced that the Food and Drug Administration (FDA) Office of Orphan Product Development has granted SLIT™ Amikacin orphan drug status for the treatment of bronchopulmonary Pseudomonas aeruginosa (Pa) infections in Cystic Fibrosis (CF) patients.